Anafen Injection 100 mg/mL (Canada)

This page contains information on Anafen Injection 100 mg/mL for veterinary use.
The information provided typically includes the following:
  • Anafen Injection 100 mg/mL Indications
  • Warnings and cautions for Anafen Injection 100 mg/mL
  • Direction and dosage information for Anafen Injection 100 mg/mL

Anafen Injection 100 mg/mL

This treatment applies to the following species:
Manufacturer: Merial

Ketoprofen Injection 100 mg/mL

Sterile Injectable Solution

Nonsteroidal Anti-inflammatory Analgesic

For Veterinary Use Only

D.I.N. 01938126

Active Ingredient

Each mL contains: 100 mg ketoprofen; L-arginine 72 mg; benzyl alcohol 1% as a preservative; citric acid added to adjust pH.

Indications: Horses: Anafen® is recommended for the alleviation of inflammation and pain associated with musculoskeletal disorders. Cattle: Anafen® is recommended for the symptomatic treatment of fever, pain and inflammation associated with a variety of conditions including: respiratory tract infections, mastitis, udder edema, downer cow syndrome, endotoxemia, simple gastrointestinal disorders, arthritis and traumatic musculoskeletal injuries. Swine: Anafen® is recommended for the treatment of fever and inflammation associated with respiratory infections.

Pharmacology

Ketoprofen is a nonsteroidal anti-inflammatory agent possessing anti-inflammatory, analgesic and antipyretic properties. Ketoprofen belongs to the propionic acid subclass of carboxylic acid derivative nonsteroidal antiinflammatory drugs, which also includes ibuprofen, naproxen and fenoprofen. The primary mechanism of action is inhibition of prostaglandin synthesis through interference with the cyclo-oxygenase pathway of arachidonic acid metabolism. Recent studies indicate that the analgesic and antipyretic effects are mediated centrally. Ketoprofen has been shown to have potent activity against acute, subacute and chronic inflammation in the classical models of inflammation. Ketoprofen has a high affinity for inflamed tissue, resulting in a therapeutic response which lasts considerably longer than can be predicted from the relatively short plasma half-life.

Horses: Doses of Anafen® ranging from 1 mg/kg (0.5 mg/lb) to 3 mg/kg (1.5 mg/lb) resulted in dose dependant anti-inflammatory effects in the chronic adjuvant carpitis model. Onset of activity is within two hours with peak response 12 hours after intravenous or intramuscular administration. Cattle: In well-controlled studies, beneficial effects have been demonstrated in a variety of disease conditions characterized by fever, inflammation and pain, including respiratory tract infections, mastitis, udder edema, downer cow syndrome, endotoxemia, simple gastrointestinal disorders, arthritis and traumatic musculoskeletal injuries. In diseases with a primary infectious etiology, Anafen® should only be used in conjunction with appropriate antimicrobial therapy. Onset of activity is rapid. After administration of Anafen®, peak plasma levels of ketoprofen and its primary metabolite are obtained in approximately 45 minutes and 3 hours, respectively. The plasma half-life is 2 hours. Eighty percent of the dose is eliminated in the urine within 24 hours following administration, primarily as the conjugated metabolite. Swine: In swine, as in other species, Anafen® administered by intramuscular route is very rapidly and completely resorbed, peak plasma concentrations are obtained less than 1 hour after the injection. In diseases with a primary infectious etiology, Anafen® should only be used in conjunction with appropriate antimicrobial therapy.

Toxicity: Horses: A 15-fold overdose of Anafen® (30 mg/kg, 15 mg/lb) resulted in laminitis on the fifth day of treatment in one of two horses. A 25-fold overdose of Anafen® (50 mg/kg, 25 mg/lb) produced inappetance, depression, icterus, recumbancy and abdominal swelling. Laboratory and necropsy examinations confirmed the presence of gastritis, nephritis and hepatitis. Doses of 2.2, 6.6 and 11.0 mg/kg (1, 3 and 5 mg/lb) given intravenously or intramuscularly for 15 days were well tolerated by horses, with no evidence of toxic effects compared to placebo treated horses. These doses are up to 5 times the recommended dose and 3 times the maximum recommended treatment duration. No adverse reactions and no toxic side effects were observed in clinical efficacy trials conducted in the U.S. in which 89 horses received a total of 445 Anafen® injections at the recommended dose and duration. Cattle: Cattle treated with 5 times the recommended dose for 5 consecutive days exhibited no untoward treatment effects based on clinical and laboratory observations. At twice the recommended dose administered during the sixth week of gestation, or between the second and ninth month of gestation. Anafen® had no effect on course of gestation, parturition, fetal development or calf viability. Abomasal erosions were observed in young veal calves treated with three times the recommended dose for six consecutive days, but not when three times the recommended dose was administered for only three days. Anafen® injections are non-irritating and very well tolerated. In clinical trials, slight, transient edema was observed in approximately five percent of the injections administered. Swine: In swine after administration by intramuscular route of a single dose of 3 mg/kg or repeated doses (3 times at 24 h interval) of 3 or 9 mg/kg/day (one or three times the recommended dose-rate), the local and general tolerance of Anafen® solution was excellent.

Dosage and Administration

Horses: 2 mg/kg (1 mL/50 kg body weight) by intravenous or intramuscular injection, once a day for up to 5 days. Cattle: 3 mg/kg (1.5 mL/50 kg body weight) by intravenous or intramuscular injection, once a day for up to 3 days. Swine: 3 mg/kg (1.5 mL/50 kg bw) by intramuscular injection, once.

Contraindications

Do not use in animals showing hypersensitivity to ketoprofen. Do not administer to animals with impaired renal function.

Warnings

Cattle: Cattle treated with Anafen® Injection at a dose rate of 3 mg/kg body weight/day for 3 consecutive days must not be slaughtered for use in food for at least 24 hours after the last treatment with this drug. Horses: Anafen® Injection is not to be administered to horses that are to be slaughtered for use in food. Swine: Swine treated with Anafen® Injection at a dose rate of 3 mg/kg bodyweight must not be slaughtered for use in food for at least 7 days after the last treatment with this drug.

Anafen Injection 100 mg/mL Caution

General: Avoid intra-arterial injections. Due to its potent analgesic effect, Anafen® may mask the signs of a serious colic/gastrointestinal problem which could require surgical correction. Horses: Anafen® has not been evaluated in foals and pony breeds, both of which are susceptible to NSAID induced gastrointestinal ulceration. Not intended for use in breeding animals as effects on fertility and reproductive function in mares and stallions have not been studied. Cattle: Antimicrobial therapy is imperative when Anafen® is used as adjunctive therapy for fever and/or inflammation in conditions with an infectious etiology. Effects on fertility and reproductive function in breeding bulls have not been evaluated. Swine: Antimicrobial therapy is imperative when Anafen® is used as adjunctive therapy for fever and/or inflammation in conditions with an infectious etiology.

How Supplied

Anafen® (Ketoprofen Injection 100 mg/mL) is available in 50 mL and 100 mL multiple dose vials.

Storage Conditions: Store at controlled room temperature 15°-25°C (59°-77°F).

Protect from exposure to direct sunlight.

®Registered trademark of Merial

Manufactured by: MERIAL Canada, Inc. - 20000 Clark Graham - Baie d'Urfé - QC, H9X 4B6

037 822997

NAC No.: 11820062

MERIAL CANADA INC.
20000 CLARK GRAHAM, BAIE D'URFÉ, QC, H9X 4B6
Telephone:   514-457-1555
Order Desk:   888-637-4251 (888-MERIAL1)
Fax:   514-457-1175
Website:   www.merial.ca
Email:   service.canada@merial.com
Every effort has been made to ensure the accuracy of the Anafen Injection 100 mg/mL information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the Canadian product label or package insert.

Copyright © 2014 North American Compendiums. Updated: 2014-09-05

(web5)